CareDx, Inc. (CDNA) fair value analysis

Nasdaq · Updated 2026-09-07

CareDx, Inc. is a healthcare company that develops and commercializes diagnostic solutions for transplant patients, focusing on monitoring organ rejection and transplant outcomes. The company operates in the United States and internationally, serving transplant centers and patients worldwide through its molecular testing and monitoring platforms.

Forward Fair Value verdict

Overvalued

Based on TickrTrends' weekly Forward Fair Value model, CDNA is trading at more than a 25% premium to estimated fair value.

CDNA currently ranks #107 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Overvalued for 3 consecutive weekly runs.

Last price: $47.85
Sector: Healthcare
12-month range: $14.77–$47.85

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: A
Leverage: Low
Margin trend: Expanding
Revenue growth: Modest
RSI zone: Neutral
50/200-day trend: Uptrend
52-week position: The top quarter of its range

What our data shows for CDNA

Our model validated 7 trailing price-to-earnings windows for CDNA, built from quarterly earnings records.
Shares are trading in the upper third of their 12-month price range of $14.77–$47.85.
The 14-day relative strength index sits at a neutral 62.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for CDNA
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent CDNA news

TickrTrends' derived news-sentiment signal for CDNA is currently leaning positive, computed from recent coverage.

CDNA Initiates Coverage by Canaccord Genuity -- Price Target Set at $65 (gurufocus.com, 2026-09-02)
TickrTrends take: Canaccord Genuity's initiation of coverage with a $65 price target provides an external valuation benchmark for CDNA at a time when TickrTrends' analysis indicates the stock is trading at overvalued levels. For investors focused on valuation metrics in the Healthcare sector, this analyst target represents a reference point to monitor against the company's current trading price and whether CDNA's valuation premium can be justified by fundamental performance. The convergence or divergence between this newly established price target and CDNA's actual trading levels may signal whether market sentiment is shifting relative to the overvaluation assessment.
A Look at CareDx Inc (CDNA) After 7.0% Gain -- GF Value $25.23 vs Price $50.83 (gurufocus.com, 2026-08-26)
TickrTrends take: CareDx Inc trades at approximately twice its GuruFocus estimated value, which aligns with TickrTrends' overvalued assessment for the Healthcare sector company. The significant gap between the $25 range valuation and the $50 trading price suggests the stock carries a substantial premium that valuation-focused investors typically monitor for potential pullback risk. Investors watching this Healthcare name should track whether the company's fundamental performance justifies maintaining this elevated multiple or whether mean reversion pressures emerge.

What people are saying

Follow the CDNA conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — TickrTrends' derived indicators for CDNA show a shift in valuation assessment this week. The DCF cross-check band changed from an overvalued designation to none, suggesting a change in the model's confidence or methodology regarding the stock's fundamental value relative to its current price. The current valuation verdict remains overvalued overall.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is CDNA stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), CDNA is trading at more than a 25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.

What is CDNA's TickrTrends verdict?

CDNA's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.

How does CDNA compare to other Healthcare stocks?

CDNA ranks #107 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is CDNA overbought or oversold?

CDNA's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

CDNA vs ACAD · CDNA vs ALKS · CDNA vs AMGN · CDNA vs DGX · CDNA vs GILD